MapLight Therapeutics, Inc. (MPLT)
NASDAQ:MPLT
Top Page
MapLight Therapeutics, Inc.
(NASDAQ:MPLT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$17.50
▲(0.06% Upside)
Action:ReiteratedDate:01/09/26
The score is held back primarily by pre-revenue financials with widening losses and increasing cash burn, partially offset by a comparatively strong, low-leverage balance sheet. Recent corporate events (large IPO/private placement and stated runway through 2027) improve near-term funding visibility, while technical indicators are mixed/neutral and valuation cannot be assessed from the provided data.
Positive Factors
Low leverage / strong balance sheet
Very low debt relative to equity gives durable financial flexibility for a clinical-stage biotech. It supports continued R&D investment, reduces short-term solvency risk, and allows the company to fund operations or opportunistic partnerships without being forced into distressed financing.
Negative Factors
Pre-revenue with widening net losses
Sustained, expanding losses are a structural risk for a clinical-stage company: absent commercial revenue the business is reliant on financing markets and milestone success. Persistent widening losses increase the likelihood of future dilutive financings and place a premium on achieving clinical proof points.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt relative to equity gives durable financial flexibility for a clinical-stage biotech. It supports continued R&D investment, reduces short-term solvency risk, and allows the company to fund operations or opportunistic partnerships without being forced into distressed financing.
Read all positive factors
MapLight Therapeutics, Inc. (MPLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$774.97M
Dividend YieldN/A
Average Volume (3M)401.63K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees109
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,373,030
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.55
Enterprise Value/Market Cap-0.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit102.14
Enterprise Value/Ebitda0.42
Forecast
1Y Price Target
$35.00Price Target Upside100.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.67
Revenue Forecast (FY)N/A
MapLight Therapeutics, Inc. Business Overview & Revenue Model
Company Description
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscar...
How the Company Makes Money
null...
MapLight Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -438.00K | -701.00K | -556.00K | -574.00K |
| EBITDA | -105.83M | -76.88M | -55.15M | -29.44M |
| Net Income | -102.83M | -77.58M | -55.71M | -30.02M |
Balance Sheet | ||||
| Total Assets | 257.22M | 136.92M | 91.41M | 39.39M |
| Cash, Cash Equivalents and Short-Term Investments | 227.17M | 108.80M | 79.77M | 27.66M |
| Total Debt | 6.01M | 6.58M | 5.92M | 6.27M |
| Total Liabilities | 23.70M | 21.72M | 20.13M | 18.52M |
| Stockholders Equity | 233.52M | 115.19M | 71.28M | 20.87M |
Cash Flow | ||||
| Free Cash Flow | -113.00M | -79.58M | -52.47M | -27.32M |
| Operating Cash Flow | -112.80M | -78.81M | -52.01M | -26.58M |
| Investing Cash Flow | -48.26M | -80.79M | -462.00K | -746.00K |
| Financing Cash Flow | 197.86M | 118.06M | 104.57M | 33.17M |
MapLight Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $774.97M | -6.46 | -81.38% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $41.35M | -0.65 | -80.00% | ― | ― | 9.63% | |
49 Neutral | $580.12K | -0.24 | ― | ― | 178.82% | -4121.10% | |
47 Neutral | $4.45M | -0.76 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $3.74M | -0.15 | -381.74% | ― | ― | 98.22% | |
43 Neutral | $4.81M | -0.12 | -215.04% | ― | -100.00% | 93.82% |
* Healthcare Sector Average
MPLT
MapLight Therapeutics, Inc.
16.98
-1.36
-7.42%
SCNI
Scinai Immunotherapeutics
0.67
-2.69
-79.99%
SNSE
Sensei Biotherapeutics
29.97
20.90
230.50%
GRI
GRI Bio
2.43
-185.17
-98.70%
DRMA
Dermata Therapeutics
1.55
-11.95
-88.52%
AZTR
Azitra Inc
0.27
-1.94
-87.65%
MapLight Therapeutics, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
MapLight updates trial timelines and highlights CNS pipeline
Positive
Jan 9, 2026
On January 9, 2026, MapLight Therapeutics announced it now expects topline Phase 2 results for its ZEPHYR and IRIS clinical trials—evaluating ML-007C-MA in schizophrenia and ML-004 in autism spectrum disorder—to be disclosed in the thi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.